ArticleAmerican journal of cancer research2025
Differentiating early-stage nasopharyngeal carcinoma from adenoidal hypertrophy via SLC40A1 expression and developing a prognostic model for disease progression.
Article in American journal of cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- SLC40A1 (iron transporter): mechanistic regulation, role in disease pathogenesis, and prospects for targeted therapy.Frontiers in cell and developmental biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the expression and diagnostic utility of solute carrier family 40 member 1 (SLC40A1) in differentiating early diagnosis of nasopharyngeal carcinoma (NPC) from adenoid hypertrophy (AH), and to develop a prognostic prediction model based on its expression.
methodsPublic databases were used to analyze SLC40A1 expression in head and neck squamous cell carcinoma (HNSC) and its association with prognosis, pathological staging, and immune infiltration. A total of 102 NPC patients, 97 AH patients, and 101 healthy controls were enrolled between October 2021 and October 2023. SLC40A1 expressions in tissues and serum were assessed via real-time reverse transcription polymerase chain reaction and Western blotting. Associations with clinicopathological features were evaluated. Receiver operating characteristic (ROC) curves evaluated diagnostic performance. Logistic regression identified prognostic factors, and a predictive model was constructed.
resultsBioinformatics analysis indicated downregulated SLC40A1 in HNSC, negatively associated with tumor (T) stage and distant metastasis (M) stage. Clinical validation showed significantly lower SLC40A1 mRNA and protein levels in NPC compared to AH and controls, with negative correlation to Epstein-Barr virus (EBV) infection (all P<0.05). Serum SLC40A1 mRNA demonstrated 90.20% sensitivity and 62.38% specificity for NPC diagnosis. When combined with EBV DNA, it yielded an improved diagnostic performance (AUC=0.913). Tumor diameter >5 cm and lymph nodes ≥2 were independent risk factors for NPC progression, while high SLC40A1 expression was protective (OR=0.140, 95% CI: 0.028-0.700). The final model achieved 91.67% sensitivity and 72.00% specificity (AUC=0.863).
conclusionSLC40A1 is significantly downregulated in NPC and may serve as a diagnostic and prognostic biomarker, especially when combined with EBV status.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.